会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 32. 发明授权
    • Purification and stabilization of peptide and protein pharmaceutical agents
    • 肽和蛋白质药剂的纯化和稳定
    • US06444226B1
    • 2002-09-03
    • US09606468
    • 2000-06-29
    • Solomon S. SteinerRodney J. WoodsJoseph W. Sulner
    • Solomon S. SteinerRodney J. WoodsJoseph W. Sulner
    • A61K914
    • A61K47/22A61K9/0019A61K9/0073A61K9/0075A61K9/14A61K9/145A61K9/1617A61K9/1676A61K38/28A61K47/6949B82Y5/00C07D241/08C07K1/30C07K1/32C07K14/605C07K14/62Y10S514/866
    • Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a diketopiperazine or competitive complexing agent to facilitate removal one or more impurities, i.e. undesirable components, from the peptide or protein. In a preferred embodiment, a peptide, such as insulin, containing one or more impurities, e.g., zinc ions, is entrapped in diketopiperazine to form a precipitate of peptide/diketopiperazine/impurity, which is then washed with a solvent for the impurity to be removed, which is a nonsolvent for the diketopiperazine and a nonsolvent for the peptide. Formulations and methods also are provided for the improved transport of active agents across biological membranes, resulting for example in a rapid increase in blood agent concentration. The formulations include microparticles formed of (i) the active agent, which may be charged or neutral, and (ii) a transport enhancer that masks the charge of the agent and/or that forms hydrogen bonds with the target biological membrane in order to facilitate transport. In a preferred embodiment, insulin is administered via the pulmonary delivery of microparticles comprising fumaryl diketopiperazine and insulin in its biologically active form. The charge on the insulin molecule is masked by hydrogen bonding it to the diketopiperazine, thereby enabling the insulin to pass through the target membrane. This method of delivering insulin results in a rapid increase in blood insulin concentration that is comparable to the increase resulting from intravenous delivery.
    • 提供了通过将肽或蛋白质掺入二酮哌嗪或竞争性络合剂来促进从肽或蛋白质中去除一种或多种杂质(即不合需要的组分)来纯化肽和蛋白质的方法。 在优选的实施方案中,将包含一种或多种杂质(例如锌离子)的肽例如包被在二酮哌嗪中以形成肽/二酮哌嗪/杂质的沉淀物,然后用溶剂洗涤以使杂质为 去除,这是二酮哌嗪的非溶剂和肽的非溶剂。 提供制剂和方法用于改善活性剂在生物膜上的转运,导致例如血药剂浓度的快速增加。 制剂包括由(i)可以带电或中性的活性剂形成的微粒,和(ii)掩蔽试剂的电荷和/或与靶生物膜形成氢键的运输增强剂,以便于 运输。 在优选的实施方案中,胰岛素经由包含富马酰二酮哌嗪和胰岛素的微粒的肺部递送以其生物活性形式施用。 胰岛素分子上的电荷被氢键键合到二酮哌嗪上,从而使胰岛素能够通过靶膜。 这种递送胰岛素的方法导致血浆胰岛素浓度的快速增加,其与由静脉内递送产生的增加相当。
    • 35. 发明申请
    • SMALL PEPTIDE SEQUENCES FOR STABILIZING BIOMOLECULES
    • 用于稳定生物分子的小肽序列
    • US20120087985A1
    • 2012-04-12
    • US13253410
    • 2011-10-05
    • Solomon S. Steiner
    • Solomon S. Steiner
    • A61K9/50B01J13/04A61K38/26A61P3/10A61K38/02A61K38/28
    • A61K38/26A61K9/0019A61K9/10A61K9/1617
    • Disclosed herein are a class of small molecules, referred to as Small Peptide Sequences (SPS), that can stabilize biomolecules, particles containing the SPS and biomolecules, and compositions and methods of making the particles. The SPS are composed solely of amino acids common to humans and too small to trigger an immunological response (typically less than seven amino acids in total) and which will self assemble into particles sufficiently small to stay in liquid suspension at a first pH, typically a non-physiological pH, but which dissociate, releasing the biomolecule entrapped therein into solution, at a second pH, typically a physiological pH. The particles contain a SPS and a biomolecule, wherein the biomolecule is entrapped with the particle, immobilized on the surface of the particle, or combinations thereof. The particle releases the biomolecule upon contact with physiological fluids.
    • 本文公开了一类称为小肽序列(SPS)的小分子,其可以稳定生物分子,含有SPS和生物分子的颗粒,以及制备颗粒的组合物和方法。 SPS仅由人类常见的氨基酸组成,太小而不能触发免疫应答(通常总共小于7个氨基酸),并且其将自我组装成足够小的颗粒,以在第一pH下停留在液体悬浮液中,通常为 非生理pH,但其解离,在第二个pH(通常为生理pH)下将包埋在其中的生物分子释放到溶液中。 颗粒含有SPS和生物分子,其中生物分子被捕获,固定在颗粒的表面上,或其组合。 颗粒在与生理液体接触时释放生物分子。